ATAI
ATAI Life Sciences N.V.
$5.84
+$0.06(+1.04%)
45
Overall
40
Value
63
Tech
34
Quality
Market Cap
$1.28B
Volume
4.49M
52W Range
$1.05 - $6.75
Target Price
$12.14
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $20.4M | $233.0K | $314.0K | $308.0K | ||
| Total Revenue | $20.4M | $233.0K | $314.0K | $308.0K | ||
| GROSS PROFIT | ||||||
| Gross Profit | $20.4M | $233.0K | $314.0K | $308.0K | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $156.2M | $144.7M | $125.8M | $103.0M | ||
| Research & Development | $48.0M | $74.3M | $62.2M | $55.5M | ||
| Research Expense | $48.0M | $74.3M | $62.2M | $55.5M | ||
| Selling, General & Administrative | $92.7M | $70.3M | $63.6M | $47.5M | ||
| General & Administrative Expenses | $92.7M | $70.3M | $63.6M | $47.5M | ||
| Salaries & Wages | -- | $500.0K | $500.0K | $500.0K | ||
| Depreciation & Amortization | -- | -- | $100.0K | $200.0K | ||
| Depreciation & Amortization | -- | -- | $100.0K | $200.0K | ||
| Amortization | $195.0K | $131.0K | $371.0K | $3.2M | ||
| Other Operating Expenses | $-15.5M | $-357.0K | $-369.0K | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-135.8M | $-144.8M | $-125.5M | $-102.7M | ||
| EBITDA | $-139.9M | $-134.1M | $-42.2M | $-149.4M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $-3.5M | $923.0K | $2.7M | -- | ||
| Intinc | $205.0K | $548.0K | $1.8M | $778.0K | ||
| Net Non-Operating Interest Income/Expense | $3.7M | $375.0K | $1.8M | $778.0K | ||
| Gain on Sale of Securities | -- | -- | $-700.0K | $3.4M | ||
| Other Income/Expense | $30.0M | $9.6M | $3.8M | $2.5M | ||
| Other Special Charges | $-852.0K | $3.1M | $-189.0K | $-484.0K | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | -- | $3.2M | $2.0M | ||
| Special Income Charges | -- | -- | $-1.0M | $-4.1M | ||
| Impairment of Capital Assets | -- | -- | $1.0M | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-140.1M | $-134.3M | $-42.9M | $-150.4M | ||
| Pre-Tax Income | $-136.6M | $-135.2M | $-39.3M | $-148.4M | ||
| INCOME TAX | ||||||
| Tax Provision | $4.0M | $6.2M | $1.0M | $-356.0K | ||
| NET INCOME | ||||||
| Net Income | $-167.8M | $-152.4M | $-40.2M | $-149.3M | ||
| Net Income (Continuing Operations) | $-167.8M | $-157.4M | $-43.9M | $-150.0M | ||
| Net Income (Discontinued Operations) | $-167.8M | $-152.4M | $-40.2M | $-149.3M | ||
| Net Income (Common Stockholders) | $-120.1M | $-152.4M | $-40.2M | $-149.3M | ||
| Normalized Income | $-108.1M | -- | -- | $-144.6M | ||
| TOTALS | ||||||
| Total Expenses | $156.2M | $144.7M | $125.8M | $103.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $138.3M | $155.7M | $158.8M | $160.2M | ||
| Average Shares Outstanding (Diluted) | -- | $155.7M | $158.8M | $160.2M | ||
| Shares Outstanding | $160.7M | $166.0M | $166.0M | $198.3M | ||
| Basic EPS | $-1.21 | $-0.98 | $-0.25 | $-0.93 | ||
| Basic EPS (Continuing Operations) | $-1.21 | $-0.98 | $-0.25 | $-0.93 | ||
| Diluted EPS | $-1.21 | $-0.98 | $-0.25 | $-0.93 | ||
| Diluted EPS (Continuing Operations) | -- | $-0.98 | $-0.25 | $-0.93 | ||
| OTHER METRICS | ||||||
| Earnings from equity interest | $-41.6M | $-16.0M | $-3.6M | $-2.0M | ||
| Earnings From Equity Interest Net Of Tax | $-41.6M | $-16.0M | $-3.6M | $-2.0M | ||
| Minority Interests | $6.4M | $5.0M | $3.7M | $780.0K | ||
| Other Gand A | $92.7M | $70.3M | $63.6M | $47.5M | ||
| Other Impairment Of Capital Assets | -- | -- | $1.0M | -- | ||
| Othspecchg | -- | -- | -- | $2.1M | ||
| Restruct | -- | -- | $3.2M | $2.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATAI | $5.84 | +1.0% | 4.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |